Pfizer (PFE) stock price slips before the bell after obesity-drug update, 2026 outlook
Pfizer shares slipped roughly 3.4% to $25.77 during Wednesday's U.S. premarket session.
Pfizer stock slides on obesity drug data, earnings; what PFE investors watch next
Pfizer Inc shares dropped roughly 3.5% to $25.77 on Tuesday as investors absorbed fresh data on its weight-loss drug alongside the company’s latest quarterly earnings.
Pfizer stock drops after obesity-drug data, even as 2026 outlook holds
Pfizer Inc. shares dropped 3.3% to $25.79 by mid-afternoon, as investors digested new weight-loss drug data alongside an unchanged 2026 forecast.
Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings
Shares of Eli Lilly and Company dropped 1.4% to $1,029.99 by midday Tuesday, sliding from a session peak of $1,048.71 and dipping as low as $1,016.15.
Pfizer stock drops on obesity-drug data and 2026 outlook — what investors watch next
Pfizer dropped 3.4% to $25.76 early Tuesday, following the release of its quarterly results alongside new data on its obesity drug. By mid-morning, roughly 31 million shares had traded hands.
Pfizer stock (PFE) edges up ahead of Feb. 3 earnings as obesity pricing shifts and RSV dispute draw focus
Pfizer Inc shares edged up roughly 0.3% to $26.51 by mid-afternoon Monday, ahead of its quarterly earnings report set for Feb. 3. The stock fluctuated between $26.34 and $26.58, with volume hitting around 34.4 million shares.
Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone
The Health Care Select Sector SPDR Fund, a popular collection of major U.S. healthcare stocks, ended Friday up roughly 0.6%, closing at $154.74. Nasdaq data indicated the fund carried a defensive bid into the weekend.
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised
Healthcare shares ended Friday stronger than the wider market following Eli Lilly’s announcement of a $3.5 billion manufacturing facility in Pennsylvania dedicated to injectable weight-loss drugs. CEO David Ricks described the new plant as “really state of the art manufacturing to last many decades to come” during a press briefing.
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week
Pfizer shares dropped 1.8% to $26.02 in early afternoon trading, having fluctuated between $25.97 and $26.39.
Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming
Pfizer shares were down 1.7% at $26.06 in late morning trade on Wednesday after the U.S. Centers for Medicare & Medicaid Services added its arthritis drug Xeljanz to the next round of Medicare drug price negotiations. CMS said the talks will run in 2026, with negotiated prices slated to take effect on Jan. 1, 2028, and companies facing a Feb. 28 deadline to sign participation agreements.
Pfizer stock rises after Medicare flags Xeljanz for 2028 price talks — what investors watch next
Pfizer’s stock jumped 2.3% to $26.50 in after-hours trading Tuesday. The boost follows the U.S. Centers for Medicare & Medicaid Services picking Pfizer’s arthritis drug Xeljanz for its upcoming Medicare drug price negotiations. Alongside Xeljanz, CMS included Gilead’s Biktarvy, AbbVie’s Botox, and Eli Lilly’s Trulicity. The agency said the 15 drugs chosen serve about 1.8 million Medicare patients and represent roughly $27 billion in Medicare drug spending.
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list
Eli Lilly and Company shares ended Tuesday down $24.22, or roughly 2.3%, at $1,039.51. In after-hours trading, the stock edged up about 0.3% to $1,042.50. The U.S. Centers for Medicare & Medicaid Services announced it selected Lilly’s Trulicity, a type 2 diabetes drug, along with 14 other medicines for 2028 price negotiations. This marks the first time the list includes some therapies covered under Medicare Part B. Last year, the agency projected that negotiated prices for the 15 drugs chosen for 2027 would cut annual spending by 36%, roughly $8.5 billion, compared to recent costs.
Pfizer stock edges up as traders brace for Feb. 3 earnings and a Fed decision
Pfizer shares climbed 0.7% to $25.84 in afternoon trading Monday, bouncing between $25.60 and $25.89 earlier. The stock had closed at $25.65 previously.
Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings
Pfizer shares dropped roughly 1.9% to $25.62 Friday afternoon, underperforming the health-care sector as the stock went ex-dividend. The Health Care Select Sector SPDR Fund dipped about 0.5%, while the SPDR S&P 500 ETF Trust inched up around 0.1%. Merck slipped about 1%, and Moderna tumbled over 7%. Trading volume for Pfizer hit roughly 24.8 million shares.
Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts
Pfizer shares ended Thursday up 0.8%, closing at $26.10 after climbing Wednesday. The stock stayed comfortably within the mid-$20s, fluctuating between $25.75 and $26.31 during the session.
Pfizer stock ticks up as ViiV exit plan and Novavax vaccine deal keep PFE in focus
Pfizer shares climbed Thursday after the company announced two deals highlighting its strategy to transform its business. By afternoon, the stock had gained roughly 0.8%, reaching $26.10.
Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention
Pfizer shares gained roughly 0.8%, hitting $25.73 by Wednesday afternoon. The Health Care Select Sector SPDR ETF climbed around 1.2%, while the S&P 500 tracker SPY edged up about 0.5%.
Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play
Novavax shares edged higher by about 1% in premarket Wednesday after announcing a licensing agreement with Pfizer for its Matrix‑M vaccine technology. The stock last changed hands at $8.28, marking a 0.98% increase.
Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land
Pfizer shares slipped 0.7% to $25.47 Tuesday afternoon, after GSK and Shionogi announced Pfizer will exit HIV-focused ViiV Healthcare in a $1.9 billion deal. Pfizer is set to get $1.88 billion for its 11.7% stake, with the deal expected to close in Q1 pending regulatory approval. That day, the stock fluctuated between $25.11 and $25.65. ViiV chair David Redfern called the move a way to “simplify the shareholder structure.” Pfizer has also cautioned investors that 2026 could be challenging, as COVID-19 product sales decline, pricing pressures mount, and key patents expire.
Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next
Johnson & Johnson shares slipped 0.4% to $218.66 on Friday, the last session before U.S. markets shut for the Martin Luther King Jr. Day holiday.
TechStock² Updates
